Systematic Review of 9 RCTs Finds CBD for Neurodevelopmental Disorders Shows Potential but Inconsistent Results
Only 9 published RCTs exist testing CBD in neurodevelopmental disorders, with some positive signals but too inconsistent to guide clinical practice.
Quick Facts
What This Study Found
Nine RCTs across ADHD, autism, intellectual disability, Tourette's, and complex motor disorders showed some positive signals but inconsistent results. Evidence is undetermined.
Key Numbers
9 RCTs total across 5 conditions. Inconsistent results. Could not perform meta-analysis.
How They Did This
Systematic review searching four databases with PROSPERO registration. Only RCTs included.
Why This Research Matters
Clinical CBD use in neurodevelopmental disorders is expanding despite an alarmingly thin evidence base.
The Bigger Picture
Patients and families are making decisions in an evidence vacuum. This is concerning for vulnerable populations.
What This Study Doesn't Tell Us
Only 9 RCTs. High heterogeneity. No meta-analysis possible.
Questions This Raises
- ?Which neurodevelopmental conditions are most likely to benefit?
- ?What doses should future trials prioritize?
Trust & Context
- Key Stat:
- Only 9 RCTs exist for CBD across all neurodevelopmental disorders
- Evidence Grade:
- Systematic review limited by very few available RCTs.
- Study Age:
- Published 2023.
- Original Title:
- A systematic review of cannabidiol trials in neurodevelopmental disorders.
- Published In:
- Pharmacology, biochemistry, and behavior, 230, 173607 (2023)
- Authors:
- Parrella, Nina-Francecsa, Hill, Aron Thomas, Enticott, Peter Gregory, Barhoun, Pamela, Bower, Isabella Simone, Ford, Talitha Caitlyn
- Database ID:
- RTHC-04835
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Does CBD work for ADHD or autism?
Not enough evidence. Only 9 RCTs exist with inconsistent results.
Is CBD safe for these conditions?
Safety data is insufficient. More research is urgently needed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04835APA
Parrella, Nina-Francecsa; Hill, Aron Thomas; Enticott, Peter Gregory; Barhoun, Pamela; Bower, Isabella Simone; Ford, Talitha Caitlyn. (2023). A systematic review of cannabidiol trials in neurodevelopmental disorders.. Pharmacology, biochemistry, and behavior, 230, 173607. https://doi.org/10.1016/j.pbb.2023.173607
MLA
Parrella, Nina-Francecsa, et al. "A systematic review of cannabidiol trials in neurodevelopmental disorders.." Pharmacology, 2023. https://doi.org/10.1016/j.pbb.2023.173607
RethinkTHC
RethinkTHC Research Database. "A systematic review of cannabidiol trials in neurodevelopmen..." RTHC-04835. Retrieved from https://rethinkthc.com/research/parrella-2023-a-systematic-review-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.